Pancreatic Metastasis from Small-Cell Neuroendocrine Cervical Cancer - A Case Report and Literature Review

Wang Y1,2,3#, Hong W3,4#, Lu J3#, Lin R5, Ling H6, Qiu H3* and Yang C3*

1Life Sciences Institute, Zhejiang University, China 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou First People's Hospital, China 3Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China 4Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, China 5Department of Radiotherapy, West China Xiamen Hospital of Sichuan University, China 6Department of Ultrasound in Gynecology and Obstetrics, Zhongnan Hospital of Wuhan University, China #These authors contributed equally to this work

^*Correspondance to: Chunxu Yang 

 PDF  Full Text Case Report | Open Access

Abstract:

Secondary tumors of the pancreas are uncommon, comprising approximately 2% to 7.2% of all pancreatic malignancies. Compared to renal cell carcinoma, hematologic malignancies, gastric cancer, and lung cancer, pancreatic involvement from primary cervical cancer is extremely rare. Furthermore, Small-Cell Neuroendocrine Cervical Carcinoma (SCNCC) is a rare subtype of cervical cancer, accounting for less than 5% of all cases. Here, we present a case of SCNCC metastasizing to the pancreas and review the literature pertaining to this uncommon occurrence. In September 2018, a 41-year-old female was diagnosed with stage IVB SCNCC, exhibiting lung metastasis. She underwent concurrent chemoradiation followed by brachytherapy. However, due to the progression of lung metastases, she received Docetaxel/Nedaplatin (DP) as second-line therapy and subsequently additional anlotinib added as third-line treatment. For two years after the initial diagnosis, abdominal imaging examinations revealed no abnormalities. Nevertheless, a followup whole-abdominal contrast-enhanced CT scan two years later suggested pancreatic metastasis. Pathological examination, guided by Endoscopic Ultrasound with Fine-Needle Aspiration (EUSFNA), confirmed the diagnosis of small-cell neuroendocrine carcinoma. Given the morphologically similarity and patient's oncological history, the pancreatic lesions were diagnosed as secondary metastasis from the previously treated SCNCC. She promptly underwent DP chemotherapy, pancreatic irradiation, and followed by further lines of treatment including Etoposide/Cisplatin (EP), Irinotecan/Platinum (IP) and Ceritinib. Although the pancreatic metastases were controlled, metastasis in other organs progressed, leading to her demise in May 2022.

Keywords:

Small-cell neuroendocrine carcinoma; Uterine cervix; Pancreatic metastasis; Case report

Cite the Article:

Wang Y, Hong W, Lu J, Lin R, Ling H, Qiu H, et al. Pancreatic Metastasis from Small-Cell Neuroendocrine Cervical Cancer - A Case Report and Literature Review. Ann Clin Case Rep. 2024; 9: 2600.